Companies press releases
Sep 22, 2022, 07:30 ET Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Sample Size of 350 Patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Gross product sales increased 79%, net product revenue increased 257% and prescriptions dispensed increased 49%, […]
Sep 19, 2022, 16:15 ET CRANBURY, N.J., Sept. 19, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted
Sep 08, 2022, 07:30 ET Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis Oral PL8177 May Provide a Safe and Tolerable Treatment Option for Ulcerative Colitis Patients CRANBURY, N.J., Sept. 8, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical
Aug 19, 2022, 07:30 ET Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022 CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that
Palatin Announces Intent to Effect Reverse Stock Split Read More »
Aug 16, 2022, 07:30 ET Independent Data Monitoring Committee Recommends Continuing Study with Sample Size Target of up to 350 Patients – up to Additional 230 Patients to be Enrolled No Safety Concerns Identified Topline Results Currently Expected Second Quarter Calendar 2023 CRANBURY, N.J., Aug. 16, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN),
Jul 26, 2022, 07:30 ET Gross product sales increased 75% andPrescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J., July 26, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced preliminary fourth quarter
May 17, 2022, 07:30 ET Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 Vyleesi® – Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarter Closed on a
May 12, 2022, 08:00 ET CRANBURY, N.J., May 12, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin” or the “Company”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that it has entered into a securities purchase agreement with institutional investors
May 11, 2022, 09:02 ET CRANBURY, N.J., May 11, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its
May 02, 2022, 13:02 ET Posters highlight Palatin’s ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J., May 2, 2022 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two poster presentations at
